Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 290 results for diarrhoea

  1. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

    Technology appraisal guidance
    Published
    12 February 2025
    View recommendations

    Sections for TA1039

  2. Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

    This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    23 November 2018
    View recommendations

    Sections for NG113

  3. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA116

  4. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    The medicines used for medical abortion can cause nausea, vomiting and diarrhoea. On average, 100 or more women in every 1,000 may get...

  5. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA881

  6. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 October 2014
    View recommendations

    Sections for TA321

  7. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    12 March 2013

  8. Research is needed to establish the efficacy and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection.

    [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant...

    Research recommendation
    Published
    9 June 2015

  9. Research is needed to establish the nature of bile acid malabsorption and whether bile acid malabsorption is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection.

    [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant...

    Research recommendation
    Published
    9 June 2015

  10. Specialist care of newborns

    reduces risk of: infections, with fewer visits to hospital as a result diarrhoea and vomiting, with fewer visits to hospital as a result...

  11. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA905

  12. Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

    Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.

    Technology appraisal guidance
    Last updated
    21 January 2016
    View recommendations

    Sections for TA70

  13. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

    Interventional procedures guidance
    Published
    23 November 2016
    View recommendations

    Sections for IPG569

  14. Faecal microbiota transplant for recurrent Clostridioides difficile infection (MTG71)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

    Medical technologies guidance
    Published
    31 August 2022
    View recommendations

    Sections for MTG71

  15. Adalimumab for the treatment of adults with psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA146